Methotrexate Drugs Market Outlook:
Methotrexate Drugs Market size was USD 633.7 million in 2025 and is anticipated to reach USD 871.2 million by the end of 2035, increasing at a CAGR of 3.6% during the forecast period, i.e., 2026-2035. In 2026, the industry size of methotrexate drugs is estimated at USD 680.1 million.
The market, despite being mature, effectively exhibits stabilized growth by evolving healthcare landscapes, economic necessity, and clinical utility. Its international position is deliberately resilient from a foundational role rather than innovation in worldwide treatment protocols. Factors, such as a rise in different cancers and rheumatoid arthritis (RA), increased cost of targeted and biologic synthetic DMARDs, and growth in healthcare facilities across emerging economies, are readily driving the market’s upliftment. According to an article published by NLM in March 2025, the RA prevalence accounts for 0.5% to 1.0%, and predominantly affects females, with a male-to-female ratio ranging from 1:2 to 1:3.
Moreover, as per an article published by the World Health Organization (WHO) in March 2025, the universal health coverage (UHC) index has readily increased from 45 to 68 over the past four years, which is also driving the market globally. Besides, the aspect of the primary healthcare (PHC) approach resulted in 75% of medical benefits, which includes saving more than 60 million lives and boosting the international life expectancy by 3.7 years by the end of 2030. Meanwhile, evolution in clinical practices, the launch of innovative delivery systems, and the National Essential Medicines Lists (NEMLs) inclusion are also uplifting the market.
